Dear Editor,

Cancer has been shown to be associated with higher risk of COVID-19 complications \[[@CR1]\]. However, data on patients with COVID-19 and an underlying hematological disease as well as on specific risks factors in this particularly immunocompromised population are scarce \[[@CR2]--[@CR5]\]. We conducted a retrospective study in a tertiary center of 1000 beds with a hematology reference center. Our ethics committee approved the study (N° CEHF 2020/06AVR/201). Between March 13 and May 15, 2020 a total of 375 consecutive patients were hospitalized with COVID-19 and among them 13 (3.4%) met the inclusion criteria of having an underlying hematological disease. Demographics, clinical characteristics and laboratory findings are summarized in Table [1](#Tab1){ref-type="table"}. The median age was 70 years (IQR 59--79) and 77% of patients were male. COVID-19 pneumonia was the admitting diagnosis for the majority of patients (n = 10, 77%) and a delayed secondary diagnosis in 3 patients (23%) with one of them being highly suspect for nosocomial infection. Diagnosis was based on the association of positive RT-PCR and CT-scan in 11 patients (85%) and on compatible CT-scan only in the two remaining. Median duration of symptoms (after exclusion of patients presenting with symptom-overlapping acute conditions) was 8 days (IQR 3--10). The most common reported symptoms were fever (n = 12, 92%), shortness of breath (n = 8, 62%) and cough (n = 5, 39%). Lymphopenia was present in 5 patients (39%) and neutropenia (grade 3 or more) in 2 patients. Therapy directed against COVID-19 included hydroxychloroquine for 10 patients (77%) with addition of methylprednisolone in 2 patients, azithromycin in 1 patient, and lopinavir/ritonavir in 1 patient.Table 1Characteristics of 13 patients with hematological disease and COVID-19All n = 13Survivors n = 7Non-survivors n = 6*P* valueDemographics and underlying hematological diseaseAge, median (IQR), years70 (59--79)60 (45--79)80 (70--83)**0.043**Sex Male10 (77)7 (100)3 (50)0.070 Female3 (23)0 (0)3 (50)Ethnicity Caucasian10 (77)5 (71)5 (83)1.000 Sub-Saharan African3 (23)2 (29)1 (17)Body mass index, kg/m^2^ Median (IQR)24.9 (23.2--27.9)25.6 (23.1--28.7)24.3 (23.4--26)0.945 18.5--24.97 (54)3 (43)4 (67)0.266 25.0--29.95 (39)4 (57)1 (17) ≥ 301 (8)0 (0)1 (17)Chronic comorbidities Pulmonary3 (23)1 (14)2 (33)0.559 Cardiac or cerebrovascular4 (31)1 (14)3 (50)0.266 Diabetes1 (8)0 (0)1 (17)0.462 Renal3 (23)1 (14)2 (33)0.559 High blood pressure2 (15)1 (14)1 (17)1.000 Obesity1 (8)0 (0)1 (17)0.462Number of comorbidities (among above-mentioned) 05 (39)4 (57)1 (17)0.394 14 (31)2 (29)2 (33) 22 (15)1 (14)1 (17) ≥ 32 (15)0 (0)2 (33)ECOG performance status before COVID-19 \< 29 (69)6 (86)3 (50)0.266 ≥ 24 (31)1 (14)3 (50)Category of hematological disease Acute leukemia2 (15)1 (14)1 (17)0.646 Chronic lymphocytic leukemia4 (31)3 (43)1 (17) Non-Hodgkin lymphoma2 (15)0 (0)2 (33) Plasma cell dyscrasia4 (31)2 (29)2 (33) Non-malignant1 (8)1 (14)0 (0)Stem cell transplant receptor No11 (85)6 (86)5 (83)1.000 Allogeneic1 (8)1 (14)0 (0) Autologous1 (8)0 (0)1 (17)Status of malignant hematological disease (n = 12) New diagnosis or first line treatment4/12 (33)3/6 (50)1/6 (17)0.766 Remission or watch and wait3/12 (25)1/6 (17)2/6 (33) Stable (no remission)2/12 (17)1/6 (17)1/6 (17) Relapsed or refractory3/12 (25)1/6 (17)2/6 (33)Most recent hematologic malignancy treatment (n = 12) Ongoing or \< 6 months7/12 (58)3/7 (43)4/5 (80)0.293 \> 6 months0/12 (0)0/7 (0)0/5 (0) Never5/12 (42)4/7 (57)1/5 (20)Number of treatment lines, median (IQR) (n = 12)1 (0--3)0 (0--2)3 (1--3)0.268Recent or ongoing treatment (\< 6 months) Chemotherapy3 (23)1 (14)2 (33)0.559 Allotransplant1 (8)1 (14)0 (0)1.000 Targeted drug1 (8)1 (14)0 (0)1.000 IMiDs3 (23)1 (14)2 (33)0.559 Proteasome inhibitor2 (15)1 (14)1 (17)1.000 Corticosteroids5 (39)2 (29)3 (50)0.592 None6 (46)4 (57)2 (33)0.592Clinical, laboratory and radiological characteristics at day 1 (unless otherwise specified)Duration of symptoms, median (IQR), days(n = 9)8 (3--10)7 (3--10)8 (1--20)1.000Symptoms Fever12 (92)7 (100)5 (83)0.462 Shortness of breath8 (62)5 (71)3 (50)0.592 Cough5 (39)3 (43)2 (33)1.000 Diarrhea4 (31)3 (43)1 (17)0.559 Nausea or vomiting2 (15)1 (14)1 (17)1.000 Sore throat2 (15)0 (0)2 (33)0.192 Nasal discharge1 (8)1 (14)0 (0)1.000 Headache1 (8)1 (14)0 (0)1.000 Muscle ache1 (8)0 (0)1 (17)0.462 Anosmia and/or agueusia0 (0)0 (0)0 (0)N/AqSOFA score \< 211 (85)7 (100)4 (67)0.192 ≥ 22 (15)0 (0)2 (33)CURB-65 score \< 28 (62)6 (86)2 (33)0.103 ≥ 25 (39)1 (14)4 (67)Positive SARS-CoV-2 RT-PCR11 (85)5 (39)6 (46)0.462Infiltrate on chest X-ray (n = 11)8/11 (73)3/11 (60)5/11 (83)0.545Lung CT-scan (n = 10) Typical for COVID-195/10 (50)4/6 (67)1/4 (25)0.333 Undetermined or atypical for COVID-194/10 (40)2/6 (33)2/4 (50) Negative1/10 (10)0/6 (0)1/4 (25)Disease extent on CT-scan (n = 10) \< 25%7/10 (70)4/6 (67)3/4 (75)1.000 25--50%2/10 (20)1/6 (17)1/4 (25) \> 50%1/10 (10)1/6 (17)0/4 (0)Laboratory findings (normal range), median (IQR) C-reactive protein, mg/L (\< 5)  At day 1\*82 (50--170)106 (50--177)78 (48--170)0.945  At day 7 (n = 12)105 (48--120)95 (22--107)119 (107--120)0.149 Hemoglobin level, mean ± SD, g/L(male 13.3--16.7; female 12.2--15)11.3 ± 2.212.5 ± 2.210.0 ± 1.4**0.037** Neutrophils/µL (1600--7000)4580 (2600--6960)6240 (2460--7880)4180 (2660--6410)0.945  Neutropenia (≥ grade 3)2 (15)1 (14)1 (17)1.000 Lymphocytes/µL (800--5000)1000 (280--3070)990 (280--3490)1595 (60--3070)0.836  Lymphopenia (any grade)5 (39)3 (43)2 (33)1.000 NLR  At day 1 (n = 12)2.7 (1.9--10.6)4.4 (2.3--14.8)2.1 (1.7--2.8)0.432  At day 3 (n = 11)3.6 (2.0--9.6)4.2 (2.4--5.8)2.3 (2.0--37.3)0.931  At day 5 (n = 10)2.2 (1.2--5.1)3.5 (1.9--5.1)1.5 (0.6--16.2)0.476 Eosinophils/µL (30--600)0 (0--10)0 (0--10)10 (0--20)0.295 Basophils/µL (\< 200)10 (0--10)10 (0--10)10 (0--20)0.628 Platelets, mean ± SD, × 10^3^/µL (150--450)141 ± 73151 ± 78129 ± 720.606 Lactate dehydrogenase, U/L (\< 250)317 (178--449)315 (172--601)326 (178--367)0.731 Aspartate aminotransferase, U/L (13--35)41 (25--62)28 (20--73)50 (27--62)0.445 Alanine aminotransferase, U/L (7--35)33 (15--57)16 (11--67)35 (28--39)1.000 Creatine kinase, U/L (n = 10) (20--180)110 (59--284)116 (59--284)84 (16--1014)0.833 Ferritin, µg/L (n = 5) (13--150)644 (161--776)644 (161--2105)401 (25--776)0.800 D-dimer, mg/L (n = 5) (\< 250)729 (359--986)544 (180--1228)986 (986--986)1.000 Fibrinogen, mg/dL (n = 8) (150--450)585 (462--699)655 (569--743)491 (400--601)0.250Treatments Hydroxychloroquine10 (77)7 (100)3 (50)0.070 Azithromycin1 (8)0 (0)1 (17)0.462 Methylprednisolone2 (15)1 (14)1 (17)1.000 Lopinavir/ritonavir1 (8)0 (0)1 (17)0.462 Antibiotics (for antibacterial purpose)9 (69)5 (71)4 (67)1.000Life support, complications and outcome Most invasive respiratory support required  Ambient air2 (15)2 (29)0 (0)0.462  Nasal cannula or mask9 (69)4 (57)5 (83)  High flow nasal cannula1 (8)1 (14)0 (0)  Mechanical ventilation1 (8)0 (0)1 (17)Documented bacterial co-infection4 (31)1 (8)3 (23)0.266ICU admission Not required6 (46)6 (86)0 (0)0.002 Declined (therapeutic limitation)5 (39)0 (0)5 (83) Yes2 (15)1 (14)1 (17)Length of stay (until death or discharge), days12 (7--16)13 (7--16)11 (7--16)0.628Data are N (%) unless otherwise specified*BMI* body mass index, *COVID*-*19* coronavirus disease 2019, *ECOG* Eastern Cooperative Oncology Group, *ICU* intensive care unit, *IQR* interquartile range, *IMiDs* Immuomodulatory Imide Drugs, *N/A* not applicable, *NLR* neutrophil to lymphocyte ratio, *RT*-*PCR* reverse transcriptase polymerase chain reaction, *SARS*-*CoV*-*2* severe acute respiratory syndrome coronavirus-2, *SD* standard derivation, *WBC* white blood cells\*Day 1 is the day of patient presentation if COVID-19 was the admitting diagnosis or the day when the secondary diagnosis of COVID-19 was made otherwiseSignificance of *P* value \< 0.05 are shown in bold

The underlying hematological diseases (Table [1](#Tab1){ref-type="table"}) were distributed as following: 4 chronic lymphocytic leukemia's (31%), 4 plasma cell dyscrasia's (31%), 2 acute myeloid leukemia's (15%) with one of them being secondary to primary myelofibrosis and the other one being a phenotype shift from early T cell precursor acute lymphoblastic leukemia, 2 non-Hodgkin lymphoma's (15%) and 1 non-malignant condition which was a chronic hypogammaglobinemia of unknown origin. Two patients were stem cell transplant receptors (1 autologous and 1 allogeneic). Four malignant hematological diseases (33%) were newly diagnosed or in first line treatment, 3 were in remission or in a watch and wait strategy without ever having had any treatment, 2 were stable without remission and 3 were relapsed or refractory. Patients received a median of 1 (range 0--5) treatment lines.

Two patients were admitted to the intensive care unit (ICU) at presentation: one received high flow oxygen therapy and the other one invasive mechanical ventilation. Five more patients (39%) presented worsening respiratory state later during hospitalization and were medically eligible for an admission to the ICU but, owing to age and comorbidities, palliative care was provided instead. Four patients (31%) had a documented bacterial co-infection (Three urinary tract infections caused by *Escherichia coli* \[[@CR2]\],and *Enterococcus faecalis* \[[@CR1]\] and one septicemia caused by *Escherichia coli* probably secondary to mucositis in a patient with febrile neutropenia). Overall, 6 patients (46%) died during their stay in our COVID-19 units (n = 5) or ICU (n = 1). Comparing survivors and non-survivors, we observed that non-survivors were significantly older than survivors with a median age of 80 \[interquartile range (IQR) 70--83\] versus 60 (IQR 45--79; *P* = 0.043) respectively. Of interest, the hemoglobin level at day 1 was lower in non-survivors \[mean ± standard derivation (SD) 10.0 ± 1.4\] than in survivors (mean ± SD 12.5 ± 2.2; *P* = 0.037) besides not being correlated to age (r = − 0.09; *P* = 0.765). No specific type, status or treatment of hematological disease was shown to be associated with a higher mortality in our series.

We identified two covariates that were significantly associated with worse outcomes in our patients: older age and lower hemoglobin level at day 1.

A higher mortality in older patients was already shown elsewhere \[[@CR3], [@CR5]\]. The association between lower hemoglobin level at presentation and a higher mortality rate was also found by Mehta et al. \[[@CR4]\]. Of interest, they demonstrate that myeloid malignancies show a trend for higher mortality compared to lymphoid malignancies. Like highlighted by Martin-Moro et al. \[[@CR3]\], it can be discussed whether this effect is intrinsic to the myeloid character of the disease or rather due to other covariates \[e.g. older age and presence of a symptom-reduction-intention treatment often present in patients with myeloproliferative neoplasm (MPN) or myelodysplastic syndromes (MDS)\] \[[@CR3]\]. In our small cohort of patients, we found no association between the myeloid/lymphoid character of the underlying disease and COVID-19 fatality (data not shown) but, to mention, our series did not include any MPN or MDS except under the form of a progression to secondary acute myeloid leukemia.

In conclusion, patients with hematologic malignancies are very vulnerable to COVID-19. Age and low hemoglobin level (on day 1) seems to be factors associated with poor outcome. Larger prospective and cohort study are needed to identify other factors associated with mortality in this population.
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